183 related articles for article (PubMed ID: 30817099)
1. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.
Kornstein SG; Bliss C; Kando J; Madhoo M
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099
[TBL] [Abstract][Full Text] [Related]
2. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.
McElroy SL; Hudson JI; Gasior M; Herman BK; Radewonuk J; Wilfley D; Busner J
Int J Eat Disord; 2017 Aug; 50(8):884-892. PubMed ID: 28481434
[TBL] [Abstract][Full Text] [Related]
3. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.
McElroy SL; Hudson J; Ferreira-Cornwell MC; Radewonuk J; Whitaker T; Gasior M
Neuropsychopharmacology; 2016 Apr; 41(5):1251-60. PubMed ID: 26346638
[TBL] [Abstract][Full Text] [Related]
4. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
[TBL] [Abstract][Full Text] [Related]
6. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
[TBL] [Abstract][Full Text] [Related]
7. Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies.
Citrome L; Kando JC; Bliss C
Neuropsychiatr Dis Treat; 2018; 14():537-546. PubMed ID: 29497297
[TBL] [Abstract][Full Text] [Related]
8. Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
McElroy SL; Mitchell JE; Wilfley D; Gasior M; Ferreira-Cornwell MC; McKay M; Wang J; Whitaker T; Hudson JI
Eur Eat Disord Rev; 2016 May; 24(3):223-31. PubMed ID: 26621156
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
10. A psychometric analysis and revalidation of the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating in adults with binge eating disorder.
Yee K; Serrano D; Kando J; McElroy SL
Qual Life Res; 2019 Dec; 28(12):3385-3394. PubMed ID: 31473907
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.
Gasior M; Hudson J; Quintero J; Ferreira-Cornwell MC; Radewonuk J; McElroy SL
J Clin Psychopharmacol; 2017 Jun; 37(3):315-322. PubMed ID: 28383364
[TBL] [Abstract][Full Text] [Related]
12. Lisdexamfetamine in Pediatric Binge Eating Disorder: A Retrospective Chart Review.
Guerdjikova AI; Blom TJ; Mori N; Matthews A; Cummings T; Casuto LL; McElroy SL
Clin Neuropharmacol; 2019; 42(6):214-216. PubMed ID: 31725476
[TBL] [Abstract][Full Text] [Related]
13. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder.
Robertson B; Wu J; Fant RV; Schnoll SH; McElroy SL
Prim Care Companion CNS Disord; 2020 Mar; 22(2):. PubMed ID: 32237290
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.
McElroy SL; Hudson JI; Mitchell JE; Wilfley D; Ferreira-Cornwell MC; Gao J; Wang J; Whitaker T; Jonas J; Gasior M
JAMA Psychiatry; 2015 Mar; 72(3):235-46. PubMed ID: 25587645
[TBL] [Abstract][Full Text] [Related]
16. Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale.
Yee KS; Pokrzywinski R; Hareendran A; Shaffer S; Sheehan DV
Int J Methods Psychiatr Res; 2021 Mar; 30(1):e1849. PubMed ID: 32841462
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
[TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine: A Review in Binge Eating Disorder.
Heo YA; Duggan ST
CNS Drugs; 2017 Nov; 31(11):1015-1022. PubMed ID: 29134566
[TBL] [Abstract][Full Text] [Related]
19. The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA.
Ágh T; Pawaskar M; Nagy B; Lachaine J; Vokó Z
Clin Drug Investig; 2016 Apr; 36(4):305-12. PubMed ID: 26914658
[TBL] [Abstract][Full Text] [Related]
20. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence.
Ezard N; Dunlop A; Hall M; Ali R; McKetin R; Bruno R; Phung N; Carr A; White J; Clifford B; Liu Z; Shanahan M; Dolan K; Baker AL; Lintzeris N
BMJ Open; 2018 Jul; 8(7):e020723. PubMed ID: 30030312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
